Redmond Asset Management LLC Boosts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Redmond Asset Management LLC boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 121,209 shares of the company’s stock after buying an additional 371 shares during the quarter. Omnicell accounts for approximately 1.3% of Redmond Asset Management LLC’s investment portfolio, making the stock its 17th largest position. Redmond Asset Management LLC owned 0.26% of Omnicell worth $5,396,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Pier Capital LLC purchased a new position in Omnicell during the third quarter worth $5,859,000. Royce & Associates LP purchased a new stake in shares of Omnicell during the third quarter valued at $811,000. Geode Capital Management LLC boosted its stake in shares of Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Omnicell by 750.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Omnicell during the third quarter valued at $753,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on OMCL shares. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Craig Hallum boosted their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company lowered their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $52.33.

Omnicell Stock Performance

OMCL stock opened at $39.72 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The business has a 50-day moving average price of $43.09 and a 200 day moving average price of $43.85. The company has a market capitalization of $1.84 billion, a P/E ratio of 147.12, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.